This study demonstrated that the binding affinity and chemoattractant properties of MCP-1 PAMs were enhanced compared to the free peptide and that MCP-1 PAMs reduced the proliferation of prostate cancer cells by decreased CCR2 expression. Here, CCL2 is linked to prostate cancer.